Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.
about
Conceptual framework for outcomes research studies of hepatitis C: an analytical reviewPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsPsychosocial issues in patients with chronic hepatitis B and CThe influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia.Psychiatric treatment considerations with direct acting antivirals in hepatitis CPsychiatric care of the patient with hepatitis C: a review of the literature.Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidencePersonality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo studyEvaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center.Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices.Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review.Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C.The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia.Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?
P2860
Q26745582-EC6EAA1D-2134-452F-BF68-1C48D46FA4A7Q26798477-9FFE7C4C-09E2-400F-9951-7EF527DAB5F7Q26824342-0346CA3F-F83E-4A45-AC11-63914ECEE7D7Q34387635-310DE0D6-5325-44B1-880C-A81A43CB1485Q34721628-B620011F-16E9-439C-8A7F-EC1F707D0673Q34743058-90E04D4F-0164-4D9F-9DAD-4CC1A126E672Q35540200-8B2A077E-D2AC-48F9-861A-D9117CC20E0FQ35749560-F4794E74-7F8A-41D2-935F-42C33DAB8942Q36896324-7BD789C9-DB8C-4378-962C-1F0F28317919Q37460279-2FE3448A-1150-4E1E-9997-C1AEA6D28A99Q37851006-2A8561EF-CDA2-40E4-8327-13993F534C9CQ38098579-A67B6E36-8865-42CB-A17C-36A3AD309E98Q42210692-22D4DF4B-B7DB-436A-A78A-A444416852A4Q42236591-5C766AAE-0E68-4BD2-A139-28414D946666Q45836877-8C823575-AC11-4518-9319-D491D1F2D665Q48612640-02F7BDED-08EB-4B5D-93E8-67FBEDCBBE25
P2860
Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Antiviral therapy completion a ...... ith and without schizophrenia.
@ast
Antiviral therapy completion a ...... ith and without schizophrenia.
@en
Antiviral therapy completion a ...... ith and without schizophrenia.
@nl
type
label
Antiviral therapy completion a ...... ith and without schizophrenia.
@ast
Antiviral therapy completion a ...... ith and without schizophrenia.
@en
Antiviral therapy completion a ...... ith and without schizophrenia.
@nl
prefLabel
Antiviral therapy completion a ...... ith and without schizophrenia.
@ast
Antiviral therapy completion a ...... ith and without schizophrenia.
@en
Antiviral therapy completion a ...... ith and without schizophrenia.
@nl
P2093
P2860
P356
P1476
Antiviral therapy completion a ...... ith and without schizophrenia.
@en
P2093
Alex Mitchell
Marilyn Huckans
Peter Hauser
Samantha Ruimy
P2860
P304
P356
10.1093/SCHBUL/SBN065
P407
P577
2008-06-17T00:00:00Z